

Market Announcement

23 June 2020

AVITA Therapeutics, Inc. (ASX: AVH) – Admission and Commencement of Official Quotation – Deferred Settlement Trading

Description

AVITA Therapeutics, Inc. ('AVH') is expected to be admitted to the Official List of ASX Limited ('ASX'), on Wednesday, 24 June 2020.

Official quotation of AVH's CHES Depositary Interests ('CDIs') representing fully paid shares of common stock at a ratio of 5:1 will commence at 10:00 AM AEST on Wednesday, 24 June 2020 on a **deferred settlement basis**.

AVH's securities are also expected to be quoted on the National Association of Securities Dealers Automated Quotations exchange ('NASDAQ'). AVH will have 21,467,912 fully paid shares of common stock on issue, of which 6,169,199 will initially be quoted on NASDAQ and 15,298,713 will initially be held by CHES Depositary Nominees Pty Limited underpinning 76,493,565 CDIs quoted on ASX.

Quotation information

Quoted Securities:	76,493,565 CDIs (indicative and subject to change)
CDI Ratio:	5:1
ASX Code:	AVHDA
Time:	10:00:00 AM +/- 15 seconds as part of Group 1 (AEST)
Date:	Wednesday, 24 June 2020
ASX Trade Abbreviation:	AVITA Ther
ISIN:	During the deferred settlement trading period (AVHDA) the ISIN will be AU0000092124. From commencement of normal trading (AVH) the ISIN will revert to AU000000AVH4.
Home Branch:	Melbourne
Registered Office:	AVITA Therapeutics, Inc. Address: C/- Corporate Creations Network, Inc., Suite 104, Tatnall Building, 3411 Silverside Road, Wilmington, New Castle County, Delaware 19810, United States of America Phone: + 1 661 367-9178 Email: investor@avitamedical.com Office of Australian local agent: Address: Mertons Corporate Services Pty Ltd Level 7, 330 Collins Street, Melbourne VIC 3000
Company Secretary:	Mark Licciardo

Share Registry:	Computershare Investor Services Pty Limited Address: Level 11, 172 St Georges Terrance, Perth, Western Australia 6000 Phone: Phone: 1300 850 505 (within Australia) or +61 3 9415 4000 (outside Australia) Email: web.queries@computershare.com.au
Balance Date:	30 June
CHESS:	Participating. CHESS and Issuer Sponsored.
Place of Incorporation:	Delaware, USA
Dividend Policy:	See section 8.6 of the Scheme Booklet
Activities:	Regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration.
Lead Manager:	Not applicable
Underwriter:	Not applicable
ASX Restricted Securities:	Nil
Other Securities Not Quoted:	1,260,524 unquoted options exercisable at various exercise prices and with various expiry dates (consolidated equivalent - see sections 12.5 and 12.6 of the Scheme Booklet). 339,359 restricted stock units (consolidated equivalent - see sections 12.5 and 12.6 of the Scheme Booklet).

The following timetable is for the deferred settlement trading in AVH's CDIs.

Date	Event
Wednesday, 24 June 2020	Commencement of Official Quotation on a deferred settlement basis – 10:00 AM AEST (ASX: AVHDA)
Monday, 29 June 2020	Last day for deferred settlement trading
Tuesday, 30 June 2020	Holding statements sent to successful applicants First day of trading on a normal (T+2) basis (ASX: AVH)
Thursday, 2 July 2020	Settlement of all on-market trades conducted on a deferred settlement basis and first settlement of trades conducted on a T+2 basis

Instructions

For further details, please refer to AVH's announcements.

What do I need to do and by when?

Please refer to AVH's Scheme Booklet.

Need more information?

For further information, please call Computershare Investor Services Pty Limited on 1300 850 505 (within Australia) or +61 3 9415 4000 (outside Australia) between 8:30am and 5:00pm (AEST) on Monday to Friday.

Disclaimer

Please refer to the following [disclaimer](#).

Issued by

Melissa Kostopoulos

Compliance Adviser, Listings Compliance (Melbourne)